GoalVest Advisory LLC Raises Position in Kenvue Inc. (NYSE:KVUE)

GoalVest Advisory LLC increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 35.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 94,897 shares of the company’s stock after purchasing an additional 24,835 shares during the period. GoalVest Advisory LLC’s holdings in Kenvue were worth $2,026,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of KVUE. Grove Bank & Trust increased its position in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after acquiring an additional 947 shares during the last quarter. Riverview Trust Co purchased a new stake in Kenvue during the 3rd quarter worth approximately $30,000. Ashton Thomas Securities LLC purchased a new stake in Kenvue during the 3rd quarter worth approximately $35,000. Fortitude Family Office LLC raised its position in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc boosted its stake in shares of Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after buying an additional 1,441 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $20.73 on Thursday. The company has a market cap of $39.75 billion, a P/E ratio of 37.70, a price-to-earnings-growth ratio of 2.00 and a beta of 1.46. The company’s fifty day moving average is $22.31 and its two-hundred day moving average is $21.75. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the prior year, the business earned $0.31 EPS. The business’s revenue for the quarter was down .4% on a year-over-year basis. Equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.95%. Kenvue’s dividend payout ratio is currently 149.09%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Barclays decreased their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. JPMorgan Chase & Co. upped their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Citigroup decreased their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Kenvue has an average rating of “Hold” and an average target price of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.